Remarkably, treatment with the USP9X inhibitor WP1130 was sufficient to achieve ERG degradation both in vivo and in vitro, thus decreasing the expression of genes associated with ERG, resulting in the inhibition of ERG-positive tumor growth in mouse xenografts [87]. This evidence concerns the gene ERG and neoplasm.